IL309468A - Biomarkers for alzheimer's disease treatment - Google Patents
Biomarkers for alzheimer's disease treatmentInfo
- Publication number
- IL309468A IL309468A IL309468A IL30946823A IL309468A IL 309468 A IL309468 A IL 309468A IL 309468 A IL309468 A IL 309468A IL 30946823 A IL30946823 A IL 30946823A IL 309468 A IL309468 A IL 309468A
- Authority
- IL
- Israel
- Prior art keywords
- biomarkers
- alzheimer
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220434P | 2021-07-09 | 2021-07-09 | |
| US202163203444P | 2021-07-22 | 2021-07-22 | |
| US202163263255P | 2021-10-29 | 2021-10-29 | |
| US202163263928P | 2021-11-11 | 2021-11-11 | |
| US202163264551P | 2021-11-24 | 2021-11-24 | |
| US202263306028P | 2022-02-02 | 2022-02-02 | |
| US202263269372P | 2022-03-15 | 2022-03-15 | |
| US202263364618P | 2022-05-12 | 2022-05-12 | |
| PCT/US2022/073576 WO2023283650A1 (en) | 2021-07-09 | 2022-07-08 | Biomarkers for alzheimer's disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309468A true IL309468A (en) | 2024-02-01 |
Family
ID=83232761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309468A IL309468A (en) | 2021-07-09 | 2022-07-08 | Biomarkers for alzheimer's disease treatment |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250163135A1 (https=) |
| EP (1) | EP4367516A1 (https=) |
| JP (1) | JP2024525559A (https=) |
| KR (1) | KR20240033017A (https=) |
| AU (1) | AU2022307687A1 (https=) |
| CA (1) | CA3225302A1 (https=) |
| CL (1) | CL2024000063A1 (https=) |
| IL (1) | IL309468A (https=) |
| MX (1) | MX2023015183A (https=) |
| TW (1) | TW202317192A (https=) |
| WO (1) | WO2023283650A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
| WO2025019457A1 (en) * | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025260029A1 (en) | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
| IL296992A (en) * | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
-
2022
- 2022-07-08 AU AU2022307687A patent/AU2022307687A1/en active Pending
- 2022-07-08 WO PCT/US2022/073576 patent/WO2023283650A1/en not_active Ceased
- 2022-07-08 EP EP22765973.7A patent/EP4367516A1/en active Pending
- 2022-07-08 CA CA3225302A patent/CA3225302A1/en active Pending
- 2022-07-08 JP JP2024500220A patent/JP2024525559A/ja active Pending
- 2022-07-08 TW TW111125802A patent/TW202317192A/zh unknown
- 2022-07-08 KR KR1020247004758A patent/KR20240033017A/ko active Pending
- 2022-07-08 IL IL309468A patent/IL309468A/en unknown
- 2022-07-08 US US18/577,174 patent/US20250163135A1/en active Pending
- 2022-07-08 MX MX2023015183A patent/MX2023015183A/es unknown
-
2024
- 2024-01-08 CL CL2024000063A patent/CL2024000063A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3225302A1 (en) | 2023-01-12 |
| JP2024525559A (ja) | 2024-07-12 |
| MX2023015183A (es) | 2024-03-14 |
| CL2024000063A1 (es) | 2024-08-02 |
| AU2022307687A1 (en) | 2024-01-04 |
| KR20240033017A (ko) | 2024-03-12 |
| EP4367516A1 (en) | 2024-05-15 |
| US20250163135A1 (en) | 2025-05-22 |
| TW202317192A (zh) | 2023-05-01 |
| WO2023283650A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309468A (en) | Biomarkers for alzheimer's disease treatment | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| CY1124257T1 (el) | N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA | |
| PT3873604T (pt) | Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina | |
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| IL280315A (en) | Methods of treatment and prevention of alzheimer's disease | |
| IL309208A (en) | Neuroactive steroid for the treatment of alzheimer's disease | |
| EP4153210A4 (en) | MULTIPLE EPITOPE VACCINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| HUE058921T2 (hu) | Bisz-kolin-tetratiomolibdát wilson-betegség kezelésére | |
| EP4061219A4 (en) | ASSESSMENT SPEECH AUDIOMETRY | |
| MA53562A (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
| IL288940A (en) | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof | |
| EP3504204A4 (en) | INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES | |
| IL288894A (en) | Methods for the assessment and treatment of Alzheimer's disease and their applications | |
| EP4021858A4 (en) | TREATMENT OF AZOLES | |
| IL312851A (en) | Sulfonamide compounds for the treatment of neurological conditions | |
| EP3823616A4 (en) | USE OF RILUZOLE PRODRUGS IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP3833435A4 (en) | DETERMINATION OF PARKINSON'S DISEASE | |
| EP3628008A4 (en) | COMPOSITION AND METHOD OF TREATMENT OF ALZHEIMER'S MORBUS | |
| DK4284387T3 (da) | Nad-forstærkelsesterapi til parkinsons sygdom | |
| IL288793A (en) | Compounds for treating respiratory disease | |
| IL286818A (en) | Mirikizumab for use in a method of treating crohns disease | |
| MA53258A (fr) | Composés pour le traitement de la maladie d'alzheimer | |
| EP4010367A4 (en) | Use of ass34 to assess alzheimer's disease progression |